|Bid||6.08 x 0|
|Ask||6.09 x 0|
|Day's Range||5.85 - 6.13|
|52 Week Range||5.17 - 14.75|
|Beta (3Y Monthly)||0.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 31, 2017 - Apr 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.63|
Theratechnologies Inc. (Theratechnologies) (TH.TO) today announced that it requested and obtained from the European Medicines Agency (EMA) an additional month to address new questions received yesterday in regard to the establishment of a post-approval registry to gather long-term data on patients taking Trogarzo® (ibalizumab) in Europe. Theratechnologies will submit responses to the EMA by the end of June 2019. Assuming a positive CHMP opinion, our plans to launch in Germany before the end of the year remain unchanged.
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that positive results from in vivo and in vitro research, using its specific Sortilin receptor platform for the treatment of triple-negative breast cancer and ovarian cancer, were published on-line in two abstracts as part of the American Society of Clinical Oncology (“ASCO”) annual conference. Theratechnologies’ new oncology technology, a conjugate of docetaxel and a Sortilin-targeting peptide, was tested in vitro and in vivo in triple-negative breast cancer (TNBC) models. To test the efficacy of this new technology in ovarian cancer, Doxorubicin was conjugated to the same Sortilin-targeting peptide.
Theratechnologies Inc. (TH.TO) today held its annual meeting of shareholders. As part of the meeting, shareholders proceeded to elect the Company’s Board of Directors for a one-year term and elected KPMG LLP, as auditors for the current fiscal year. In addition, shareholders approved the renewal of the shareholder rights plan.
MONTREAL, May 14, 2019 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer,.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Theratechnologies Inc. (TSX:TH) is the hands-down choice of investors in the biotech industry. The stock is primed for exponential growth in the coming months.
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that the Scientific Advisory Group HIV/Viral Diseases (SAG), convened by the Committee for Medicinal Products for Human use (CHMP) in Europe, has given a positive recommendation to Trogarzo® (ibalizumab). The meeting between the SAG and representatives from Theratechnologies took place this morning in Amsterdam, Netherlands. The positive recommendation represents an important step towards the potential approval of Trogarzo® in Europe, which could constitute the second most important market for our product,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.
MONTREAL, April 04, 2019 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the first quarter ended February 28, 2019. First.
Questor Technology Inc. (TSX:QST) and three other Canadian stocks could provide high growth in areas sheltered from a potential recession.
Theratechnologies Inc. (Theratechnologies) (TH.TO) today announced that top-line results, from a study funded by the National Institutes of Health led by Dr. Steve Grinspoon and conducted at the Massachusetts General Hospital and Harvard Medical School and the National Institutes of Health, conclude that tesamorelin significantly reduces liver fat in HIV patients with Non Alcoholic Fatty Liver Disease (NAFLD) which was the primary endpoint of the study.
Theratechnologies Inc. (Theratechnologies) (TH.TO) today announced the appointment of Ms. Sheila M. Frame as a new independent member to its Board of Directors. “Sheila is a seasoned pharmaceutical executive who brings deep knowledge of the United States and other international markets. “Her appointment is in line with the announcement we made during our last annual meeting of shareholders in May 2018 to the effect that we would be looking to add new board members given how our Company was growing,” added Ms. Svoronos.
MONTREAL, March 28, 2019 -- Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the first quarter ended February.
Facilities in Wuxi City, China and Shanghai, China, have both been certified by the EMA following thorough inspections in January 2019. More than ever, we are actively preparing for an approval in this territory to ensure that key markets will be receptive to this unique breakthrough treatment for patients with multidrug resistant HIV”, said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc. Theratechnologies (TH.TO) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV.
While Theratechnologies Inc. (TSE:TH) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 19% in the last quarter. But over fiveRead More...
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that new data, presented today at the 26th annual Conference on Retroviruses and Opportunistic Infections (CROI), show that Trogarzo® (ibalizumab-uiyk) injection maintains viral suppression at week 96. Patients rolled over into the TMB-311 trial had, at baseline, a median viral load of 21,700 copies/mL. 19% of patients had a viral load ≥100,000 copies/mL.
Theratechnologies'(TSX:TH) stock is on the verge of breaking out. In full growth mode, the company is a good bet for triple-digit returns.
Theratechnologies Inc. (Theratechnologies) (TH.TO) today announced that Trogarzo® will be reviewed by the Scientific Advisory Group HIV/Viral Diseases (SAG) of the Committee for Medicinal Products for Human use (CHMP) in Europe. The SAG is convened at the request of the CHMP to provide independent recommendations on scientific or technical matters relating to human immunodeficiency virus (HIV) and viral-disease products under evaluation by the CHMP, or on any other scientific issue relevant to the work of the CHMP that relates to this area. The CHMP aims to convene the SAG in early April.
“An IV slow push could offer an option over the current IV infusion which would reduce the time of administration and eliminate the need for saline solution and other infusion apparatus,” said Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies Inc. Theratechnologies (TH.TO) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV.
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce the acquisition of Katana Biopharma Inc. (Katana) and its targeted oncology technology platform. Founded in 2016 by a group of renowned scientists led by Dr. Richard Béliveau, Katana developed a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. “Being involved in research and development and building a pipeline are essential to any specialty pharmaceutical company.
Theratechnologies Inc. (Theratechnologies) (TH.TO) today announced its financial results for the year ended November 30, 2018. “We have every reason to rejoice at what was accomplished during our last fiscal year. The launch of Trogarzo® is proving to be the game changer we thought it would become once launched in the United States while EGRIFTA® continues to deliver growth and leverage.